Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis

Table 1

The Cancer Genome Atlas (TCGA) ovarian serous cystadenocarcinoma (OVs) patient characteristics.

Characteristics	Number of cases	Percentages
Clinical stage
Stage I	1	0.27
Stage II	22	5.9
Stage III	293	78.55
Stage IV	57	15.28
Primary therapy outcome
SD	22	7.28
PD	27	8.94
PR	43	14.24
CR	210	69.54
OS
Alive	146	38.83
Dead	230	61.17
Cancer status
Tumor free	85	25.68
With tumor	246	74.32
Histologic grade
G1	1	0.27
G2	42	11.48
G3	322	87.98
G4	1	0.27
Tumor residual disease
NRD	66	19.82
RD	267	80.18
Anatomic neoplasm subdivision
Unilateral	101	28.53
Bilateral	253	71.47
Age
<60	198	52.66
≥60	178	47.34

SD: stable disease; PD: progressive disease; PR: partial remission; CR: complete remission; OS: overall survival; NRD: no residual disease; RD: residual disease.